• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过筛查发现宫颈异常的终生概率较高。

High lifetime probability of screen-detected cervical abnormalities.

作者信息

Pankakoski Maiju, Heinävaara Sirpa, Sarkeala Tytti, Anttila Ahti

机构信息

1 Finnish Cancer Registry, Helsinki, Finland.

2 Faculty of Medicine, University of Helsinki, Finland.

出版信息

J Med Screen. 2017 Dec;24(4):201-207. doi: 10.1177/0969141316685740. Epub 2017 Jan 10.

DOI:10.1177/0969141316685740
PMID:28073308
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5661699/
Abstract

Objective Regular screening and follow-up is an important key to cervical cancer prevention; however, screening inevitably detects mild or borderline abnormalities that would never progress to a more severe stage. We analysed the cumulative probability and recurrence of cervical abnormalities in the Finnish organized screening programme during a 22-year follow-up. Methods Screening histories were collected for 364,487 women born between 1950 and 1965. Data consisted of 1 207,017 routine screens and 88,143 follow-up screens between 1991 and 2012. Probabilities of cervical abnormalities by age were estimated using logistic regression and generalized estimating equations methodology. Results The probability of experiencing any abnormality at least once at ages 30-64 was 34.0% (95% confidence interval [CI]: 33.3-34.6%) . Probability was 5.4% (95% CI: 5.0-5.8%) for results warranting referral and 2.2% (95% CI: 2.0-2.4%) for results with histologically confirmed findings. Previous occurrences were associated with an increased risk of detecting new ones, specifically in older women. Conclusion A considerable proportion of women experience at least one abnormal screening result during their lifetime, and yet very few eventually develop an actual precancerous lesion. Re-evaluation of diagnostic criteria concerning mild abnormalities might improve the balance of harms and benefits of screening. Special monitoring of women with recurrent abnormalities especially at older ages may also be needed.

摘要

目的 定期筛查和随访是预防宫颈癌的重要关键;然而,筛查不可避免地会检测到一些轻度或临界异常,而这些异常永远不会进展到更严重的阶段。我们分析了芬兰有组织筛查计划中22年随访期间宫颈异常的累积概率和复发情况。方法 收集了1950年至1965年出生的364487名女性的筛查史。数据包括1991年至2012年期间的1207017次常规筛查和88143次随访筛查。使用逻辑回归和广义估计方程方法估计不同年龄宫颈异常的概率。结果 30至64岁女性至少有一次出现任何异常的概率为34.0%(95%置信区间[CI]:33.3 - 34.6%)。需要转诊结果的概率为5.4%(95%CI:5.0 - 5.8%),组织学确诊结果的概率为2.2%(95%CI:2.0 - 2.4%)。既往出现异常与检测到新异常的风险增加相关,尤其是在老年女性中。结论 相当一部分女性在一生中至少有一次筛查结果异常,但最终很少有人会发展为实际的癌前病变。重新评估关于轻度异常的诊断标准可能会改善筛查的利弊平衡。对于反复出现异常的女性,尤其是老年女性,可能也需要进行特殊监测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/738a/5661699/f7bdda5ab27f/10.1177_0969141316685740-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/738a/5661699/c8093aea8df4/10.1177_0969141316685740-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/738a/5661699/f7bdda5ab27f/10.1177_0969141316685740-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/738a/5661699/c8093aea8df4/10.1177_0969141316685740-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/738a/5661699/f7bdda5ab27f/10.1177_0969141316685740-fig2.jpg

相似文献

1
High lifetime probability of screen-detected cervical abnormalities.通过筛查发现宫颈异常的终生概率较高。
J Med Screen. 2017 Dec;24(4):201-207. doi: 10.1177/0969141316685740. Epub 2017 Jan 10.
2
Population-based organized cervical cancer screening pilot program in France.法国基于人群的有组织宫颈癌筛查试点项目。
Eur J Cancer Prev. 2018 Sep;27(5):486-492. doi: 10.1097/CEJ.0000000000000365.
3
Screening for cervical cancer: recommendation statement.宫颈癌筛查:推荐声明。
Am Fam Physician. 2012 Sep 15;86(6):555-9.
4
Aboriginal women have a higher risk of cervical abnormalities at screening; South Australia, 1993-2016.原住民女性在筛查中出现宫颈异常的风险更高;南澳大利亚,1993-2016 年。
J Med Screen. 2019 Jun;26(2):104-112. doi: 10.1177/0969141318810719. Epub 2018 Nov 12.
5
Age-specific effectiveness of the Finnish cervical cancer screening programme.芬兰宫颈癌筛查计划的年龄特异性效果。
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1354-61. doi: 10.1158/1055-9965.EPI-12-0162. Epub 2012 Jun 4.
6
The agreement between self-reported cervical smear abnormalities and screening programme records.自我报告的宫颈涂片异常情况与筛查项目记录之间的一致性。
J Med Screen. 2006;13(2):72-5. doi: 10.1258/096914106777589687.
7
High-grade cervical abnormalities and screening intervals in New South Wales, Australia.澳大利亚新南威尔士州的高级别宫颈异常与筛查间隔
J Med Screen. 2008;15(1):36-43. doi: 10.1258/jms.2008.007036.
8
Cervical Cancer Screening and Incidence by Age: Unmet Needs Near and After the Stopping Age for Screening.按年龄划分的宫颈癌筛查和发病情况:接近和超过筛查停止年龄后的未满足需求。
Am J Prev Med. 2017 Sep;53(3):392-395. doi: 10.1016/j.amepre.2017.02.024. Epub 2017 May 1.
9
Factors associated with cervical precancerous lesions among women screened for cervical cancer in Addis Ababa, Ethiopia: A case control study.埃塞俄比亚亚的斯亚贝巴宫颈癌筛查女性中与宫颈癌前病变相关的因素:一项病例对照研究。
PLoS One. 2018 Jan 19;13(1):e0191506. doi: 10.1371/journal.pone.0191506. eCollection 2018.
10
Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands.监测一项全国性癌症预防计划:荷兰宫颈癌筛查的成功变革
Int J Cancer. 2007 Feb 15;120(4):806-12. doi: 10.1002/ijc.22167.

引用本文的文献

1
Effect of Test History at Ages 50-64 on Later Cervical Cancer Risk: A Population-based Case-control Study.50-64 岁时的检测史对后期宫颈癌风险的影响:基于人群的病例对照研究。
Cancer Res Commun. 2023 Sep 11;3(9):1823-1829. doi: 10.1158/2767-9764.CRC-23-0191. eCollection 2023 Sep.

本文引用的文献

1
Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis.宫颈上皮内瘤变治疗后的生育力及早期妊娠结局:系统评价与荟萃分析
BMJ. 2014 Oct 28;349:g6192. doi: 10.1136/bmj.g6192.
2
Divergent coverage, frequency and costs of organised and opportunistic Pap testing in Finland.芬兰组织性和机会性巴氏涂片检查的覆盖范围、频率和费用存在差异。
Int J Cancer. 2014 Jul 1;135(1):204-13. doi: 10.1002/ijc.28646. Epub 2013 Dec 18.
3
The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland.
HPV 所致女性生殖器疾病的预防和管理负担及成本:芬兰基于人群的注册研究。
Int J Cancer. 2013 Sep 15;133(6):1459-69. doi: 10.1002/ijc.28145. Epub 2013 Apr 5.
4
Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.一次人乳头瘤病毒 DNA 初筛检测中对癌前和癌性宫颈病变的检出率:芬兰的一项前瞻性随机试验。
BMJ. 2012 Nov 29;345:e7789. doi: 10.1136/bmj.e7789.
5
Age-specific effectiveness of the Finnish cervical cancer screening programme.芬兰宫颈癌筛查计划的年龄特异性效果。
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1354-61. doi: 10.1158/1055-9965.EPI-12-0162. Epub 2012 Jun 4.
6
Large performance variation does not affect outcome in the Finnish cervical cancer screening programme.在芬兰宫颈癌筛查项目中,较大的性能差异不会影响筛查结果。
Cytopathology. 2012 Jun;23(3):172-80. doi: 10.1111/j.1365-2303.2011.00849.x. Epub 2011 Jan 24.
7
Marginal and mixed-effects models in the analysis of human papillomavirus natural history data.分析人乳头瘤病毒自然史数据的边缘和混合效应模型。
Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):159-69. doi: 10.1158/1055-9965.EPI-09-0546.
8
Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.在随机环境中对原发性人乳头瘤病毒筛查与传统细胞学进行特定年龄评估。
J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.
9
Process performance of cervical screening programmes in Europe.欧洲宫颈筛查项目的流程绩效
Eur J Cancer. 2009 Oct;45(15):2659-70. doi: 10.1016/j.ejca.2009.07.022. Epub 2009 Aug 25.
10
Cervical cancer screening policies and coverage in Europe.欧洲的宫颈癌筛查政策与覆盖率
Eur J Cancer. 2009 Oct;45(15):2649-58. doi: 10.1016/j.ejca.2009.07.020. Epub 2009 Aug 19.